Patents by Inventor Grifols, S.A.

Grifols, S.A. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140113355
    Abstract: A process for obtaining an IgG composition involves heat treatment. This process obtains an IgG composition from an IgG solution partly purified from human plasma, in which by applying intermediate heat treatment and without using reagents to precipitate high molecular weight aggregates/polymers and/or proteins virtually total elimination of the IgG polymers generated during the process is achieved. Furthermore this process offers high productivity, lower production costs and is easy to implement in comparison with the processes of the know art. In addition to this, by using this process stability is imparted to the final product in liquid.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 24, 2014
    Applicant: Grifols, S.A.
    Inventor: Grifols, S.A.
  • Publication number: 20130289528
    Abstract: Devices, systems, and methods for delivery of therapeutics, in particular thrombolytic agents, in particular plasmin, are provided. The devices, systems, and methods also provide for occlusion of a vessel or graft distal and/or proximal to a treatment zone. Also provided are devices, systems, and methods that trap emboli.
    Type: Application
    Filed: April 9, 2013
    Publication date: October 31, 2013
    Inventor: Grifols, S.A.
  • Publication number: 20130164273
    Abstract: The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. In another aspect of the invention, the fibrinolytic composition of the present invention comprises a reversibly inactivated acidified plasmin substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent.
    Type: Application
    Filed: February 7, 2013
    Publication date: June 27, 2013
    Applicant: Grifols, S.A.
    Inventor: Grifols, S.A.